Venous Thromboembolism – Current Treatment – Detailed, Expanded Analysis- Treatment Algorithms: Claims Data Analysis (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current therapies include treatment and secondary prophylaxis with anticoagulants, as well as acute treatment with thrombolytics in the case of severe events such as PE. Among all anticoagulant drugs, non-vitamin K antagonist oral anticoagulants (NOACs) have gained popularity in recent years and have become drivers of market growth. Nonetheless, low-molecular-weight heparins (LMWHs) are still widely prescribed. This analysis of claims data provides a quantitative picture of prescribing patterns for newly diagnosed and recently drug-treated VTE patients in the United States.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed VTE patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed VTE patients?
- How have NOACs been integrated into the treatment algorithm, and what is their source of business?
- What percentage of VTE patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of VTE patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Market covered: United States
Key companies: Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Mylan, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Genentech
Key drugs: Dabigatran etexilate mesylate, argatroban, dalteparin sodium, enoxaparin sodium, heparin sodium, fondaparinux sodium, apixaban, edoxaban, rivaroxaban, warfarin, alteplase
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
- Venous Thromboembolism - Current Treatment - Detailed, Expanded Analysis- Treatment Algorithms: Claims Data Analysis (US)
- Treatment Algorithms CDA Venous Thromboembolism US March 2023
- Treatment Algorithms CDA Venous Thromboembolism 2023 Dashboard
Laia Martínez-Carreres, M.Sc., Ph.D., Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematological Disorders. Dr. Martinez-Carreres has authored reports on polycystic kidney disease, venous thromboembolism, and atrial fibrillation. Prior to joining Clarivate, she was a clinical research project manager at Parc Taulí Hospital (Spain). She holds a Ph.D. in biomedical sciences from the University of Lausanne, where she studied the role of the cell cycle-related protein CDK4 in metabolism in the laboratory of Professor Lluis Fajas. She also holds a master’s degree in translational medicine and a bachelor’s degree in biomedical sciences, both from the University of Barcelona. Dr. Martínez-Carreres also trained as a data analyst at EADA Business School in Spain.